e low prevalence rate and limited literature on eccrine carcinoma (EC) pose a challenge to properly diagnosing and treating this rare malignancy. EC lesions tend to present similarly to other cutaneous neoplasms and dermatitis-like conditions. E cacious treatment guidelines have not been established for patients diagnosed with EC, and few treatment regimens have demonstrated clinical bene t. Due to the high metastatic potential of EC, recognizing the clinical presentation, properly diagnosing, and utilizing bene cial treatment options are important for managing this disease. We report a case of a 66-year-old female who presented with lesions that her primary care provider misdiagnosed as basal cell carcinoma. e disease responded poorly to taxane-and platinum-based chemotherapies as well as an isolated limb perfusion of an alkylating agent. However, continuous dosing of oral capecitabine achieved an 18-month period of progression free survival (PFS) and ameliorated quality of life. We wish to highlight this rare disease and discuss presentation, diagnosis, and management as it is most often misdiagnosed leading to advanced metastatic disease when patients present to the oncologist. In addition, it is crucial to study and report potentially e cacious regimens considering the lack of clinical trials in this disease.
Introduction
Eccrine carcinoma (EC) is an appendageal cancer that originates from the eccrine sweat gland and accounts for an estimated 0.005-0.01% of diagnosed cutaneous malignancies [1] . Histopathologies closely associated with EC include hidroadenocarcinoma, spiradenocarcinoma, and porocarcinoma [1] [2] [3] . A consistent clinical presentation of these lesions has not been identi ed; other authors have reported brown, bluish, and erythematous lesions which may appear papular or ulcerative [1, 4, 5] . Proper recognition and diagnosis of EC prove to be di cult due to its infrequency and similar presentation to basal and squamous cell carcinoma, amelanotic melanoma, seborrheic keratosis, cutaneous lymphoma, and verruca vulgaris [1] .
EC lesions are commonly reported in the lower extremities (35%), head and neck (24%), and upper extremities (14%) [1] . Immunohistochemical (IHC) stains and serum cancer markers have also been inconsistently reported, which include but are not limited to carcinoembryonic antigen, epithelial membrane antigen, estrogen receptors, progesterone receptors, cytokeratin 7, and pancytokeratins [2, 6] .
us, recognizing the pleomorphic features of basaloid cells within the epidermis that in ltrate into the ductal papillary structures of the dermis help diagnose EC [2] .
A limited understanding of EC in addition to unestablished treatment guidelines contributes to a relative mortality rate of 80% and a 10-year disease survival rate of 9% when metastatic in stage [1, 7] . Based on the current literature, there seems to be a clinical consensus that wide surgical excision with the goal of clear margins is the most e ective treatment for locoregional EC [8] . However, this option is not optimal for metastatic cases [9] . Other cases of metastatic EC have illustrated resistance to radiotherapy as well as a variety of chemotherapies [9] . We describe a case of a patient who continued to progress during treatments with carboplatin, paclitaxel, melphalan, actinomycin D, and radiotherapy but achieved 18 months of progression free survival (PFS) and an improved quality of life with oral capecitabine despite her di usely metastatic disease. (Figure 2(a) ) as well as recurrence in the left leg (Figure 2(b) ).
Case Description
In February 2012, the patient started a capecitabine regimen (1500 mg PO q12h) that followed a 2-week on/1-week o dosing schedule. Due to grade 3 palmar-plantar erythrodysesthesia syndrome occurring 12 months after dosing, the dose was reduced to 1000 mg. e absence of cutaneous lesion recurrence was noted. CT studies (Figure 2 ) revealed an overall partial response with a decrease in size of the left pelvic lymph node metastases (Figure 2(c) ) and cutaneous lesions in the left leg (Figure 2(d) ). Capecitabine was continued until August 2013 when new cutaneous metastases appeared in the left gluteus (1.3 cm) and right anterior breast (1.7 cm). CT studies showed interval enlargement of left pelvic lymph node, right adrenal, and pulmonary metastases (Figures 3(a)  and 3(c) ). New metastatic disease was identi ed in the thoracic and abdominal lymph nodes, the right pleura, and cutaneous tissue (Figure 3(c) ). An MRI of the brain revealed multiple metastases with index lesions in the right posterior parietal lobe (Figures 3(b) and 3(d) ). e patient was referred to palliative care and hospice; she expired shortly after.
Discussion
Treatment strategies have been reported (Table 1) and illustrate the resistant nature of EC to numerous chemotherapies with only a few options increasing patient survival. Patients treated with platinum-based, taxane-based, and tyrosine kinase inhibitors seem not to derive a substantial therapeutic bene t.
e tyrosine kinase inhibitor, sunitinib, achieved 8 months of PFS after a patient progressed through prior platinum-based therapy [10] . Poor outcomes are also noted with the anthracycline antibiotic, doxorubicin, and monotherapy with cyclophosphamide; EC rapidly progressed with metastases into multiple organs and the patients expired soon after [4, 11] .
Distinct tumor markers have not been characterized for EC, and other authors have reported a variety of positive IHC stains [2, 6, 13] . us, correlative studies of biomarkers can help develop targeted therapies aimed at speci c pathways and genetic mutations [2, 13] . For example, a case was reported of a patient with metastatic EC whose tumor biopsy revealed 100% reactivity for estrogen and progesterone receptors; the patient was started on empirical tamoxifen citrate therapy and achieved 3 years of complete remission [13] . On the other hand, our patient had negative reactivity for both of these receptors, so molecular pro les need to be identi ed and the prevalence assessed. A study that evaluated the molecular pro les of apocrine-eccrine carcinoma cases found that 6 of the 7 EC cases tested positive for the epidermal growth factor receptor (EGFR) mutant [14] . is highlights a potential role for clinical trials to determine the outcomes of targeted therapies that correspond to pertinent oncogene mutations [14] .
To the best of our knowledge, we report the third case of metastatic EC treated with capecitabine [5, 12] . Our patient continued on capecitabine dosing from February 2012 to August 2013 without disease progression. Per RECIST version 1.1 criteria, our patient's follow-up CT study (Figures 2(c) and 2(d) ) showed a partial response two months after starting capecitabine treatment. is regimen of oral capecitabine a orded e cacy and improved the patient's quality of life compared to the doublet therapy of carboplatin and paclitaxel which had more toxicities. e high mortality and morbidity rates associated with metastatic EC indicate the necessity for clinical trials to fully delineate safety and e cacy of potential future therapies [1] [2] [3] 9] .
Conclusion
Eccrine carcinoma is an uncommon skin cancer that accompanies a poor prognosis. e clinical presentation of EC can be equivocal and result in misdiagnosis, which adversely a ects patient outcomes. Standard of care treatment options for metastatic EC have not yet been developed. Further investigation into the e cacy of capecitabine treatment as monotherapy or in combination with other regimens for metastatic EC is worthwhile to improve the poor outcomes of diagnosed patients. Moreover, correlation of molecular pro les to tumor responses would provide helpful data to identify e cacious treatment regimens in the future.
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